<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119458">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02061670</url>
  </required_header>
  <id_info>
    <org_study_id>TR007</org_study_id>
    <nct_id>NCT02061670</nct_id>
  </id_info>
  <brief_title>Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma</brief_title>
  <official_title>A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to
      subjects suffering from both ragweed allergy and asthma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Throughout subjects participation in the study, approximately 22 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with asthma exacerbations as a measure of safety and tolerability</measure>
    <time_frame>Throughout subjects participation in the study, approximately 22 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of change in lung function as a measure of safety and tolerability</measure>
    <time_frame>Throughout subjects participation in the study, approximately 22 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Ragweed-SPIRE 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ragweed-SPIRE regimen 1 given 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ragweed-SPIRE 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ragweed-SPIRE regimen 2 given 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given 2 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ragweed-SPIRE</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>Ragweed-SPIRE 1</arm_group_label>
    <arm_group_label>Ragweed-SPIRE 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-65 years.

          -  Asthma treated by inhaled SABA or inhaled SABA plus low-medium dose ICS in 6 weeks
             prior to randomisation.

          -  A reliable history consistent with moderate to severe rhinoconjunctivitis on exposure
             to ragweed for at least the previous two ragweed seasons.

          -  Positive skin prick test to ragweed

          -  Ragweed-specific Immunoglobulin E (IgE) â‰¥ 0.35 kU/L.

        Exclusion Criteria:

          -  History of life-threatening asthma.

          -  Uncontrolled asthma according to GINA

          -  FEV1 of &lt; 70 % of predicted, regardless of the cause.

          -  Administration of adrenaline (epinephrine) is contraindicated (e.g. subjects with
             acute or chronic symptomatic coronary heart disease or severe hypertension).

          -  History of severe drug allergy or anaphylactic reaction to food.

          -  A history of any significant disease or disorder (e.g. immune system, pulmonary,
             cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal,
             endocrine, metabolic, malignant, psychiatric, major physical impairment, history of
             alcohol or drug abuse)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deborah Bates</last_name>
    <email>deborah.bates@pharm-olam.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kanata Allergy Services</name>
      <address>
        <city>Kanata</city>
        <state>Ontario</state>
        <zip>K2L 3C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles W Frankish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Ellis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheema Research Inc</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5A 3V</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amarjit Cheema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Allergy Research Corp</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inflamax Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>L4W 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Janice Faulknor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>February 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ragweed</keyword>
  <keyword>Allergy</keyword>
  <keyword>rhinoconjunctivitis</keyword>
  <keyword>rhinitis</keyword>
  <keyword>asthma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
